Ann: Botanix Webinar - Presentation Copy, page-172

For those who missed BOT Webinar 17 September 2024, just a rough summary jotted below if you're interested re Main Points. Copied and pasted from Word so don't know how it will turn out! All I can say is that I am in for the long haul on this stock - IMHOO it will eventually pop and soar!

· BOT dermatology focused company, common skin diseases (acne, rosacea, Primary Axillary Hyperhidrosis (PAH) underarm sweating etc.). Lots going on, in the pipeline!

· BOT world class team successfully launched >30 products previously

· Commercial readiness for Sofdra FDA approved June, 2024 treatment for PAH aged 9yrs+

· Cash in Bank $79mil used for commercial launch, development of platform

· Platform deep dive combines patient targeting, telemedicine, reimbursement management, direct fulfillment capabilities etc.

· Stock Soared around 130% last 6mths (Mkt Cap$762mil, 1.8bil shares o/s)

· BOT has NO Outstanding Debt

· Top 20 SHs hold around 34% holdings

· 2 x Offices (Philadelphia and recently opened commercial office in Phoenix, Arizona)

· Discussed 5 Buckets 1. Surveys 2. Commercial Plan (patient experience program Q42024) 3. Digital Platform (unique - patient acquisitions) 4. Telemedicine Platform 5. Reimbursement / Contracting

1. Survey (Lisa)

Survey May, 2024 by Aust. Analyst (ENP) – 136 participants, US residents, 18yrs+, confirmed PAH sufferers. What did we learn?

PAH sufferers are willing to deal with side effects.

PAH sufferers will use a product even if it means it will reduce their sweating by half. i.e. PAH sufferers are so desperate to reduce the underarm sweating cause it’s distressing, embarrassing and socially challenging.

NOTES:-

95% ofparticipants said that if they knew a prescription topical gel was clinically proven to be more effective at reducing underarm sweating than available OTC products they would be “likely or very likely to try it.”

And side effects? Eg. Dry mouth. 75% said that side effects would impact their decision to try the topical gel only “a little” or “none at all.”

Most impt criteria (in order) for participants when choosing between treatments?

Cost (participants don’t know cost Sofdra), side effects (BUT participants didn’t know side effects), not having to go to doctors, easy to use, recommendation from people, easily available.

How much does the treatment have to reduce your sweating for you to at least strongly consider to try it? 55% reduction

2. Commercial Plan (Howie)

3 Phase approach next 12mths.

Phase 1 engage commercial patients, optimise platform, appropriate patients early, sales force leadership (district manager, sales mgr already hired starts next week or so).

Phase 2 focus on physicians, AI targeted digital campaign (focusing core group prescribers who are very productive see lots PAH patients)

Real time data received

Phase 3 expand / optimise call on additional physicians, expansion of targets in digital campaign. Show how to maximise growth.

16mil hyperhidrosis patients in US, 10mil have PAH (underarm sweating) 3.7mil patients diagnosed in past year. BUT we looked back in last decade we saw that 70% of all PAH patients have been diagnosed. Key insight – increases speed of patient acting, many already met insurance coverage, big upside actionable immediately.

Sales Force – finalise hiring 3 x field managers next week. They will finalise their own teams in next few mths, sales reps will complete home study & attend live launch meeting at end January and some starting immediately afterwards. Focus on where patients are located i.e. 4500 positions that write vast majority of dermatology prescriptions i.e. 3 Regions with 9 x sales persons per region. Uncovered areas? Digitally, conferences etc. Majority here though is covered by the SalesForce Team.

Last 3 months leading up to launch meeting? Focused on creating / testing the imagery / messages - materials for the sales team to use in digital campaign.

Patient Experience Program – participant surveys, feedback, telemedicine, how to improve program, will provide first revenues, help to prepare for full commercial launch / expansion by June. Participants self selected. Lisa will run this i.e. surveys, webinars, feedback etc. Balance 18,000 further target patients can get product enables further testing. Gets ready for full digital launch in January.

GOAL – Gun Team ensure the patient experience is flawless throughout.

3. Digital Platform (Jay Manara - Klick Health)

Est 1997 dermatology expertise, world’s largest, many awards blah blah but awesome for BOT! What will they do?

Lots of Corporate Spin / Big Brother stuff! Data Sets / Tools, use health data to ID audiences, validate medical need, where are they in personal treatment journey, leverage these targeting data sets to engage them. Online behaviours eg. OTC purchases, are they online reading about hyperhidrosis? Online highly active looking for solutions, social conversations etc. Moment of need targeting social channels.

4. Telemedicine Platform (George Jones UpScript)

Upscript est 2001 experienced with pharma co’s etc. very impt for patients who despise / wont go to see their GP - done from comfort of own home.

Process? Patient will create account; complete online questionnaire critical for clinicians who gather information to make treatment decision; schedule app’t with clinician if appropriate (video / audio) but often prescription signed off without clinician app’t. Electronic prescription, concierge service ensure rapid flawless treatment. Seamless journey. Median time payment to visit completed 17 hours – shortest time was 2 minutes! 7 days / 24 hrs access online quest., access clinician if need be 6 a.m. to midnight. Answer call time is 6 seconds. Avg time to engage patient is 4 min. Efficient / Effective pacing journey! Credit card payment. 4-16 weeksto see a dermatologist specialist in the US!

5. Reimbursement / Payout Engagement (John)

Sofdra Coverage – 90% patients to be able to get Sofdra will some type of coverage.

About 1/3 of patients will have the ability to get Sofdra covered with no restrictions.

35% label, age, diagnosis, tried / failed previous OTC or prescription treatment *many already tried other treatments

3^rd bucket – more in depth review of patient’s condition.

Engage reach 1mil commercial patients. In January, launch AI digital campaign etc. In June, will know potential growth BOT.

Sofdra builton 3 Main Pillars:–
Ensure we take advantage of the large market opportunity – 16 million patients have hyperhidrosis – it’s the 3^rd largest dermatological condition out there!
10Mil have PAH (7Mil diagnosed – *this is the basis of all BOT’s targeting).
3.7mil are already in the physician office – Field Sales Force will get good % of these.
Just activating a very small % of the other 6.3mil patients who aren’t seeing a physician will be incredible.
Create Frictionless access to Telemedicine (immediate / comfortable access, move them from diagnosis to prescription)
Speed to patient so they get every single refill, avoid distributor fees / other costs by using direct fill every time, drive positive patient outcome, profitability.

And to you BOT, in the words of Ben Graham, "in the short run the market is a voting machine but in the long run it is a weighing machine.” BOT's success and value will eventually be truly recognised - it's a steal at 41c. Be patient people, it will pay off! Vision, Courage, Patience! Only the patient here will bear the fruits of their labours and retire with a smile! GLTAH IMHOO